Puma Biotechnology Stock Shoves It in Short Sellers' Faces

Shares of Puma Biotechnology are up almost 300% after the company posted strong top-line results for its flagship cancer drug neratinib. Here's what investors need to know moving forward.

Jul 23, 2014 at 4:01PM

Biotech stocks are not for the faint of heart by any stretch of the imagination. Puma Biotechnology (NYSE:PBYI) has repeatedly shown the investing world why this is the case, and today's 200% plus movement upward should drive this point home. 

PBYI Chart

PBYI data by YCharts

After soaring by over 350% last year, Puma has fallen hard in recent months due to a mysterious case of investor pessimism for its cancer drug PB272, aka neratinib. Specifically, Puma shares cratered by 25% in a single day after the company earlier this year announced partial midstage trial results for neratinib as a potential treatment for breast cancer that has spread to the brain.

What bummed investors out apparently was that neratinib produced severe diarrhea in a number of patients participating in the study. As I mentioned previously, I found this panic selling to be overdone at the time, largely because neratinib's undesirable side-effect profile was known prior to the company licensing the drug from Pfizer (NYSE:PFE). Moreover, this particular type of adverse effect(NYSE:PFE)can be managed effectively through the proactive use of antidiarrheals, and Puma has taken the steps to do so in its ongoing trials.  

Pfizer turns pessimistic, makes a stunningly bad business decision 
The investing community was apparently not alone in thinking that neratinib's commercial potential was overblown. Pfizer this week amended its licensing agreement with Puma for neratinib, pushing the bulk of clinical trial expenses onto Puma and giving up a nice chunk of potential royalty payments in the process.

Per the new agreement, Puma is now responsible for funding the ongoing legacy trials for neratinib, which will substantially increase the company's expenses moving forward. By the same token, Pfizer is now only entitled to a percentage of royalties on net sales in the low to mid teens (previously up to 20%).

Puma has the last laugh
Almost immediately after announcing this amended agreement, Puma on Tuesday released top-line data from a late-stage study for neratinib as a treatment for HER2-positive breast cancer. According to the release, patients receiving neratinib showed a whopping 33% increase in disease-free survival, or DFS, compared to placebo. The company plans on filing for regulatory approval in early 2015.

Neratinib would enter a market that already sports a megablockbuster in Roche's Herceptin. Although neratinib's exact role in the clinic for early stage HER2-positive breast cancer patients remains to be seen, the drug's path toward blockbuster status certainly became a lot easier after Puma posted these strong trial results.

Foolish wrap-up
I think the market and Pfizer's combined pessimism stemmed mainly from the failure of GlaxoSmithKline's drug Tykerb to significantly improve DFS in its late-stage trial for HER2-positive breast cancer patients in an adjuvant setting. Indeed, a number of drugs have failed to outperform Herceptin for this indication, and neratinib looked like it was going to be the next victim. Now that neratinib has shown to improve clinical outcomes for HER2-positive patients in a large late-stage study, it should become an important part of the breast cancer pharma landscape. Which of course begs the question as to whether Puma therefore could be a prime takeover target. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers